Mark Larche

Title: Mark Larche: Innovator in Tumor Diagnosis and Therapy

Introduction

Mark Larche is a notable inventor based in Worcester Park, GB. He has made significant contributions to the field of medical science, particularly in the diagnosis and therapy of tumors. With a total of 2 patents, his work focuses on innovative compounds that enhance treatment options for patients.

Latest Patents

Larche's latest patents include groundbreaking inventions related to compounds for the diagnosis and therapy of tumors. These compounds are designed for use as immunosuppressive agents and include antibodies that bind to IL-4 receptors. A preferred compound is the monoclonal antibody MR-6, which is produced by a hybridoma deposited at the European Collection of Animal Cell Cultures with the accession number 88033002. His inventions also extend to the use of these compounds for the in vitro removal of graft-versus-host reactive T-lymphocytes prior to bone marrow transplantation. Additionally, he has developed a novel protein with a molecular weight of 200,000 daltons that functions as a receptor for IL-4.

Career Highlights

Mark Larche is affiliated with the Royal Postgraduate Medical School of Hammersmith Hospital, where he continues to advance his research and innovations. His work has been instrumental in improving therapeutic strategies for tumor treatment, showcasing his commitment to enhancing patient care through scientific discovery.

Collaborations

One of his notable collaborators is Mary Alice Ritter, with whom he has worked on various projects aimed at improving medical outcomes through innovative research.

Conclusion

Mark Larche's contributions to the field of tumor diagnosis and therapy highlight his role as a leading inventor in medical science. His innovative patents and ongoing research efforts continue to pave the way for advancements in treatment options for patients facing challenging health conditions.